Reska Biotech

Reska Biotech Equity

The The Equity of Reska Biotech (GWIN) as of Nov 4, 2026 is -99,186.00 USD. In the previous year, The Equity was -113,854.00 USD — a change of -12.88% (higher).

Equity

-99,186.00USD

YoY

-12.88%

Last updated:

In 2022, Reska Biotech's equity was -99,186.00 USD, a -12.88% increase from the -113,854.00 USD equity in the previous year.

The Reska Biotech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
-270,000.00 USD
Jan 1, 2016
-33,011.00 USD
Jan 1, 2017
-99,186.00 USD
Jan 1, 2018
-113,854.00 USD
Jan 1, 2022
-99,186.00 USD
The Reska Biotech Equity history
YEAREquityYoY
-99,186.00USD-12.88%
-113,854.00USD+14.79%
-99,186.00USD+200.46%
-33,011.00USD-87.77%
-270,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Reska Biotech Stock analysis

What does Reska Biotech do? The Glorywin Entertainment Group Inc is a Hong Kong-based company that specializes in the production, management, and marketing of entertainment content. The company was founded in 2005 and has been listed on the Canadian stock exchange since 2015. Glorywin's business model is based on the production and marketing of entertainment content in various sectors. This includes film and television production, music labels, event management, as well as the management and marketing of artists and celebrities. Over the years, the company has developed and produced a variety of products. In the film and television sector, these include TV series such as "The Four Detective Guards," "Journey to the East," "Ten Deadly Sins," and "Saviors in the Forbidden City." In addition, Glorywin has also produced films for the cinema such as "The Four," "Kung Fu Angels," and "The White Storm." Musically, the company is primarily active in the Asian pop industry and operates its own label with well-known artists such as Coco Lee and Janice Vidal. Another important business area for Glorywin is event management. The company organizes concerts, festivals, and other events in China and other Asian countries. The most well-known events include the "MTV Super Summit," the "Pepsi Music Festival," and the "Hong Kong Asian-Pop Music Festival." Glorywin often collaborates with other companies to reach a wider audience. In addition to the production of entertainment content and event management, Glorywin also operates its own leisure facilities. The goal is to make the brand and products of the company accessible to a broader audience. The company primarily focuses on theme parks and interactive museums. Currently, Glorywin operates the "Three Kingdoms City" theme park in China and the "Cool & Ice World" museum in Hong Kong. In recent years, the company has also focused on the digital media sector. Glorywin operates its own social media platform for fans and has developed a chatbot system for interactive communication with customers. The goal is to position and market the brand and products even more strongly in the digital world. To coordinate and manage all these activities, Glorywin has built an experienced team of managers and producers. The company works closely with international partners and collaborators to develop innovative products and events that excite the audience and tap into new markets. Overall, the company has become an important player in the Asian entertainment industry in recent years and has achieved numerous successes. This success is supported by the increasing popularity of Asian pop music, TV series, and films worldwide. In the future, Glorywin will likely continue to focus on these trends and attempt to establish itself in new markets. Reska Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Reska Biotech's Equity

Reska Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Reska Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Reska Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Reska Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Reska Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Reska Biotech stock

The Equity of Reska Biotech is -99,186.00 USD in 2022.

The Equity of Reska Biotech changed from -113,854.00 USD to -99,186.00 USD, representing a -12.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Reska Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Reska Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Reska Biotech

All Key Metrics — Reska Biotech